Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor

Journal of Medicinal Chemistry

Volumn 55, Issue 20, 2012, Pages 8809-8826

  Favia, Angelo D ^a   Habrant, Damien ^a,d   Scarpelli, Rita ^a   Migliore, Marco ^a   Albani, Clara ^a   Bertozzi, Sine Mandrup ^a   Dionisi, Mauro ^a   Tarozzo, Glauco ^a   Piomelli, Daniele ^a,b   Cavalli, Andrea ^a,c   De Vivo, Marco ^a  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (6 CHLORO 9 (2 METHOXYBENZYL) 9H CARBAZOL 2 YL)PROPANOIC ACID; 2 (6 CHLORO 9 (3 METHOXYBENZYL) 9H CARBAZOL 2 YL)PROPANOIC ACID; 2 (6 CHLORO 9 (4 CHLOROBENZYL) 9H CARBAZOL 2 YL)PROPANOIC ACID; 2 (6 CHLORO 9 (4 CYANOBENZYL) 9H CARBAZOL 2 YL)PROPANOIC ACID; 2 (6 CHLORO 9 (4 METHOXYBENZYL) 9H CARBAZOL 2 YL)PROPANOIC ACID; 2 (6 CHLORO 9 (HEXYLSULFONYL) 9H CARBAZOL 2 YL)PROPANOIC ACID; 2 (6 CHLORO 9 METHYL 9H CARBAZOL 2 YL)PROPANOIC ACID; 2 (6 CHLORO 9H CARBAZOL 2 YL) N (2 HYDROXYETHYL) PROPANAMIDE; 2 (6 CHLORO 9H CARBAZOL 2 YL) N PHENYLPROPANAMIDE; 2 (9 BENZOYL 6 CHLORO 9H CARBAZOL 2 YL)PROPANOIC ACID; 2 (9 BENZYL 6 CHLORO 9H CARBAZOL 2 YL)PROPANOIC ACID; 2 (9H CARBAZOL 2 YL)PROPANOIC ACID; 2 [6 CHLORO 9 (4 CHLOROBENZOYL) 9H CARBAZOL 2 YL]PROPANOIC ACID; 2 [6 CHLORO 9 (4 FLUOROBENZOYL) 9H CARBAZOL 2 YL]PROPANOIC ACID; 2 [6 CHLORO 9 (4 METHOXYBENZOYL) 9H CARBAZOL 2 YL]PROPANOIC ACID; 2 [6 CHLORO 9 (CYCLOHEXYLCARBAMOYL)CARBAZOL 2 YL]PROPANOIC ACID; 2 [6 CHLORO 9 (HEXYLCARBAMOYL) 9H CARBAZOL 2 YL]PROPANOIC ACID; 2 [6 CHLORO 9 (HEXYLMETHYLCARBAMOYL)CARBAZOL 2 YL]PROPANOIC ACID; 2 [6 CHLORO 9 (METHYLCARBAMOYL)CARBAZOL 2 YL]PROPANOIC ACID; 2 [6 CHLORO 9 (OCTYLCARBAMOYL) 9H CARBAZOL 2 YL]PROPANOIC ACID; 2 [6 CHLORO 9 [(4 CHLOROPHENYL)CARBAMOYL] 9H CARBAZOL 2 YL] PROPANOIC ACID; 2 [6 CHLORO 9 [(4 CHLOROPHENYL)SULFONYL] 9H CARBAZOL 2 YL] PROPANOIC ACID; 2 [9 (BUTYLCARBAMOYL) 6 CHLORO 9H CARBAZOL 2 YL]PROPANOIC ACID; CARPROFEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FATTY ACID AMIDASE; LIGAND; METHYL 2 (6 CHLORO 9H CARBAZOL 2 YL)PROPANOATE; UNCLASSIFIED DRUG; AMIDASE; ANALGESIC AGENT; CARBAZOLE DERIVATIVE; FATTY-ACID AMIDE HYDROLASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL TISSUE; ARTICLE; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; NONHUMAN; RAT; BINDING SITE; CHEMISTRY; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; MOLECULAR DOCKING; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMIDOHYDROLASES; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING SITES; CARBAZOLES; CYCLOOXYGENASE INHIBITORS; IMMUNOENZYME TECHNIQUES; MOLECULAR DOCKING SIMULATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867750821     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3011146     Document Type: Article

References (63)

1. Wilson, K. G.; Eriksson, M. Y.; DEon, J. L.; Mikail, S. F.; Emery, P. C. Major depression and insomnia in chronic pain Clin. J. Pain 2002, 18, 77-83
2. Morin, C. M.; Gibson, D.; Wade, J. Self-reported sleep and mood disturbance in chronic pain patients Clin. J. Pain 1998, 14, 311-314
3. Menefee, L. A.; Frank, E. D.; Doghramji, K.; Picarello, K.; Park, J. J.; Jalali, S.; Perez-Schwartz, L. Self-reported sleep quality and quality of life for individuals with chronic pain conditions Clin. J. Pain 2000, 16, 290-297
4. Stahl, S.; Briley, M. Understanding pain in depression Hum. Psychopharmacol. 2004, 19 (Suppl. 1) S9-S13
5. Linton, S. J. A review of psychological risk factors in back and neck pain Spine (Philadelphia) 2000, 25, 1148-1156
6. Fishbain, D. A. The association of chronic pain and suicide Semin. Clin. Neuropsychiatry 1999, 4, 221-227
7. Tang, N. K.; Crane, C. Suicidality in chronic pain: a review of the prevalence, risk factors and psychological links Psychol. Med. 2006, 36, 575-586
8. Kurumbail, R. G.; Kiefer, J. R.; Marnett, L. J. Cyclooxygenase enzymes: catalysis and inhibition Curr. Opin. Struct. Biol. 2001, 11, 752-760
9. Blobaum, A. L.; Marnett, L. J. Structural and functional basis of cyclooxygenase inhibition J. Med. Chem. 2007, 50, 1425-1441
10. Rouzer, C. A.; Marnett, L. J. Cyclooxygenases: structural and functional insights J. Lipid Res. 2009, 50 (Suppl.) S29-S34
11. Marnett, L. J. The COXIB experience: a look in the rearview mirror Annu. Rev. Pharmacol. Toxicol. 2009, 49, 265-290
12. Naesdal, J.; Brown, K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options Drug Saf. 2006, 29, 119-132
13. Topol, E. J. Failing the public health-rofecoxib, Merck, and the FDA N. Engl. J. Med. 2004, 351, 1707-1709
14. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.-C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Léger, S.; Mancini, J.; ONeill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Thérien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778
15. Piomelli, D. The endocannabinoid system: a drug discovery perspective Curr. Opin. Invest. Drugs (BioMed Cent.) 2005, 6, 672-679
16. Gaetani, S.; Dipasquale, P.; Romano, A.; Righetti, L.; Cassano, T.; Piomelli, D.; Cuomo, V. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs Int. Rev. Neurobiol. 2009, 85, 57-72
17. Gobbi, G.; Bambico, F. R.; Mangieri, R.; Bortolato, M.; Campolongo, P.; Solinas, M.; Cassano, T.; Morgese, M. G.; Debonnel, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Mor, M.; Trezza, V.; Goldberg, S. R.; Cuomo, V.; Piomelli, D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 18620-18625
18. Clapper, J. R.; Moreno-Sanz, G.; Russo, R.; Guijarro, A.; Vacondio, F.; Duranti, A.; Tontini, A.; Sanchini, S.; Sciolino, N. R.; Spradley, J. M.; Hohmann, A. G.; Calignano, A.; Mor, M.; Tarzia, G.; Piomelli, D. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism Nat. Neurosci. 2010, 13, 1265-1270
19. Kathuria, S.; Gaetani, S.; Fegley, D.; Valino, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of anxiety through blockade of anandamide hydrolysis Nat. Med. 2003, 9, 76-81
20. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 1992, 258, 1946-1949
21. Piomelli, D. The molecular logic of endocannabinoid signalling Nat. Rev. Neurosci. 2003, 4, 873-884
22. Piomelli, D. A thickening network of lipids Pain 2012, 153, 3-4
23. Fowler, C. J. NSAIDs: eNdocannabinoid stimulating anti-inflammatory drugs? Trends Pharmacol. Sci. 2012, 33 (9) 468-473
24. Fowler, C. J.; Bjorklund, E.; Lichtman, A. H.; Naidu, P. S.; Congiu, C.; Onnis, V. Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. J. Enzyme Inhib. Med. Chem. 2012, in press.
25. Seierstad, M.; Breitenbucher, J. G. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors J. Med. Chem. 2008, 51, 7327-7343
26. Otrubova, K.; Ezzili, C.; Boger, D. L. The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH) Bioorg. Med. Chem. Lett. 2011, 21, 4674-4685
27. Palermo, G.; Branduardi, D.; Masetti, M.; Lodola, A.; Mor, M.; Piomelli, D.; Cavalli, A.; De Vivo, M. Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas J. Med. Chem. 2011, 54, 6612-6623
28. Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimaraes, C. R.; Jorgensen, W. L.; Cravatt, B. F. Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics J. Med. Chem. 2005, 48, 1849-1856
29. Clapper, J. R.; Vacondio, F.; King, A. R.; Duranti, A.; Tontini, A.; Silva, C.; Sanchini, S.; Tarzia, G.; Mor, M.; Piomelli, D. A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo ChemMedChem 2009, 4, 1505-1513
30. Vacondio, F.; Silva, C.; Lodola, A.; Fioni, A.; Rivara, S.; Duranti, A.; Tontini, A.; Sanchini, S.; Clapper, J. R.; Piomelli, D.; Mor, M.; Tarzia, G. Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability ChemMedChem 2009, 4, 1495-1504
31. Johnson, D. S.; Stiff, C.; Lazerwith, S. E.; Kesten, S. R.; Fay, L. K.; Morris, M.; Beidler, D.; Liimatta, M. B.; Smith, S. E.; Dudley, D. T.; Sadagopan, N.; Bhattachar, S. N.; Kesten, S. J.; Nomanbhoy, T. K.; Cravatt, B. F.; Ahn, K. Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor ACS Med. Chem. Lett. 2011, 2, 91-96
32. Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies J. Med. Chem. 2004, 47, 4998-5008
33. Naidu, P. S.; Booker, L.; Cravatt, B. F.; Lichtman, A. H. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception J. Pharmacol. Exp. Ther. 2009, 329, 48-56
34. Sasso, O.; Bertorelli, R.; Bandiera, T.; Scarpelli, R.; Colombano, G.; Armirotti, A.; Moreno-Sanz, G.; Reggiani, A.; Piomelli, D. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions Pharmacol. Res. 2012, 65, 553-563
35. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
36. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543
37. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multi-target drugs: the network approach might help drug design Trends Pharmacol. Sci. 2005, 26, 178-182
38. Zimmermann, G. R.; Lehar, J.; Keith, C. T. Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discovery Today 2007, 12, 34-42
39. Holt, S.; Paylor, B.; Boldrup, L.; Alajakku, K.; Vandevoorde, S.; Sundstrom, A.; Cocco, M. T.; Onnis, V.; Fowler, C. J. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin Eur. J. Pharmacol. 2007, 565, 26-36
40. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs Nucleic Acids Res. 2011, 39, D1035-D1041
41. Huang, N.; Shoichet, B. K.; Irwin, J. J. Benchmarking sets for molecular docking J. Med. Chem. 2006, 49, 6789-6801
42. Berger, L.; Corraz, A. J. Carbazoles. US 3869145.
43. Narlawar, R.; Perez Revuelta, B. I.; Haass, C.; Steiner, H.; Schmidt, B.; Baumann, K. Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer γ-secretase modulators J. Med. Chem. 2006, 49, 7588-7591
44. Bishay, P.; Schmidt, H.; Marian, C.; Haussler, A.; Wijnvoord, N.; Ziebell, S.; Metzner, J.; Koch, M.; Myrczek, T.; Bechmann, I.; Kuner, R.; Costigan, M.; Dehghani, F.; Geisslinger, G.; Tegeder, I. R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids PLoS One 2010, 5, e10628
45. Fowler, C. J.; Borjesson, M.; Tiger, G. Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase Br. J. Pharmacol. 2000, 131, 498-504
46. Duggan, K. C.; Walters, M. J.; Musee, J.; Harp, J. M.; Kiefer, J. R.; Oates, J. A.; Marnett, L. J. Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen J. Biol. Chem. 2010, 285, 34950-34959
47. Fowler, C. J.; Tiger, G.; Stenstrom, A. Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship J. Pharmacol. Exp. Ther. 1997, 283, 729-734
48. Fowler, C. J.; Janson, U.; Johnson, R. M.; Wahlstrom, G.; Stenstrom, A.; Norstrom, K.; Tiger, G. Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen Arch. Biochem. Biophys. 1999, 362, 191-196
49. Fowler, C. J.; Naidu, P. S.; Lichtman, A.; Onnis, V. The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1 Br. J. Pharmacol. 2009, 156, 412-419
50. Fowler, C. J.; Holt, S.; Tiger, G. Acidic nonsteroidal anti-inflammatory drugs inhibit rat brain fatty acid amide hydrolase in a pH-dependent manner J. Enzyme Inhib. Med. Chem. 2003, 18, 55-58
51. Hermanson, D. J.; Marnett, L. J. Cannabinoids, endocannabinoids, and cancer Cancer Metastasis Rev. 2011, 30, 599-612
52. Marnett, L. J. Inflammation and cancer: chemical approaches to mechanisms, imaging, and treatment J. Org. Chem. 2012, 77, 5224-38
53. Nobeli, I.; Favia, A. D.; Thornton, J. M. Protein promiscuity and its implications for biotechnology Nat. Biotechnol. 2009, 27, 157-167
54. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A 'rule of three' for fragment-based lead discovery? Drug Discovery Today 2003, 8, 876-877
55. Czarnobilski, Z.; Bem, S.; Czarnobilski, K.; Konturek, S. J. Carprofen and the therapy of gastroduodenal ulcerations by ranitidine Hepatogastroenterology 1985, 32, 20-23
56. Duggan, K. C.; Hermanson, D. J.; Musee, J.; Prusakiewicz, J. J.; Scheib, J. L.; Carter, B. D.; Banerjee, S.; Oates, J. A.; Marnett, L. J. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2 Nat. Chem. Biol. 2011, 7, 803-809
57. Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling Science 2002, 298, 1793-1796
58. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents Nature 1996, 384, 644-648
59. Krivov, G. G.; Shapovalov, M. V.; Dunbrack, R. L., Jr. Improved prediction of protein side-chain conformations with SCWRL4 Proteins 2009, 77, 778-795
60. Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R. D.; Kale, L.; Schulten, K. Scalable molecular dynamics with NAMD J. Comput. Chem. 2005, 26, 1781-1802
61. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins 2006, 65, 712-725
62. Sanner, M. F. Python: a programming language for software integration and development J. Mol. Graphics Modell. 1999, 17, 57-61
63. Trott, O.; Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 2010, 31, 455-61